Developer docs
API playgroundTry for free, no card

Search company profiles

Flex Pharma

Full company profile

uuid000u1ej

Namestring
Flex Pharma
Legal namestring
Flex Pharma, Inc.
Websiteurl
flex-pharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Flex Pharma was a clinical-stage biopharmaceutical company founded in 2014 by Nobel Laureate Rod MacKinnon, M.D. (2003 Nobel Prize in Chemistry) and Harvard neurobiology professor Bruce Bean, Ph.D., both National Academy of Science members. The company's core technology centered on chemical neurostimulation through activation of Transient Receptor Potential (TRP) ion channels — specifically TRPV1 and TRPA1 — to reduce alpha-motor neuron hyperexcitability and thereby prevent or treat muscle cramps, spasms, and spasticity. Its two product lines were HOTSHOT, a direct-to-consumer sports shot for endurance athletes that used organic, non-GMO, NSF-Certified ingredients to activate TRP channels orally; and FLX-787, a proprietary drug candidate in clinical development targeting cramps, spasms, and spasticity associated with ALS, Multiple Sclerosis, and other neurological conditions.

The company generated revenue through two distinct streams: consumer product sales of HOTSHOT via its own e-commerce storefront (a product-led, one-time-purchase model), and prospective licensing/royalty economics from future commercialization of FLX-787. GTM was hybrid — direct-to-consumer for HOTSHOT targeting endurance athletes, and clinical-development-led for FLX-787 with presentations at AAN, ASENT, ACTRIMS, SFN, ACSM, and ECTRIMS medical conferences. The company was headquartered at 800 Boylston St., 24th Floor, Boston, MA, raised $40M in a 2014 funding round from investors including Bessemer Venture Partners, Spark Capital, Longwood Fund, and Lightstone Ventures, and was associated with NASDAQ ticker FLKS. Notably, as of 2025 the flex-pharma.com domain appears to have been repurposed as a Canadian online pharmacy affiliate selling generic erectile dysfunction medications (Cialis/Viagra), suggesting the original biotech operations have ceased.

Short descriptiontext

Flex Pharma was a clinical-stage biopharmaceutical company that developed chemical neurostimulation technology (TRPV1/TRPA1 ion channel activators) for muscle cramps and spasticity, commercializing the HOTSHOT consumer sports product and the FLX-787 drug candidate.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
muscle cramp treatment, neuromuscular disorder therapy, TRP ion channel therapeutics, sports nutrition shots, chemical neurostimulation
Industry3 codes
PRIMARYCRADAGAA
Sports Nutrition (Protein, Creatine, Pre-Workout/Intra-Workout)
SECONDARYHLAKALAB
Sports Medicine
SECONDARYHSADAFAD
Sports Nutrition & Performance Fueling
NAICS code2 codes
  • Sporting and Athletic Goods Manufacturing33992
  • Food (Health) Supplement Retailers456191
SIC code2 codes
  • Sporting & Athletic Goods, Nec3949
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Neuromuscular Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1HOTSHOT Consumer Product Sales
TypeOne Time License
Description

Direct-to-consumer sales of HOTSHOT, a sports nutrition product marketed to endurance athletes for preventing and treating muscle cramps. The product is NSF Certified for Sport, non-GMO Project Verified, and USDA Certified Organic.

flex-pharma.com
2Drug Development (FLX-787)
TypeLicensing Royalties
Description

Development of pharmaceutical products for neuromuscular disorders including FLX-787 for cramps, spasms, and spasticity associated with neurological conditions such as ALS and Multiple Sclerosis.

flex-pharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1HOTSHOT
Description

A proprietary sports shot with a kick, scientifically proven to prevent and treat muscle cramps. Non-GMO Project Verified, USDA Certified Organic product that is NSF Certified for Sport. Invented by Nobel Prize-winning neuroscientist Rod MacKinnon.

flex-pharma.com
Core offering1 text field

Flex Pharma develops treatments for muscle cramps and spasms grounded in proprietary chemical neurostimulation technology that activates TRPV1 and TRPA1 ion channels. Its commercial offering is HOTSHOT, a consumer sports nutrition shot marketed to endurance athletes for preventing and treating muscle cramps, while its clinical-stage offering is FLX-787, a drug candidate targeting cramps, spasms, and spasticity in neurological disorders such as ALS and Multiple Sclerosis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Flex Pharma is a biopharmaceutical company developing treatments for neuromuscular disorders with two distinct product lines: HOTSHOT, a consumer sports nutrition product marketed to endurance athletes for preventing muscle cramps; and FLX-787, a proprietary drug candidate in clinical development targeting muscle cramps and spasticity associated with neurological conditions through a novel chemical neurostimulation mechanism.

Product and service2 records
1HOTSHOT
CategorySports nutrition consumer product
Description

A proprietary sports shot invented by Nobel Laureate Rod MacKinnon, scientifically proven to prevent and treat muscle cramps. Formulated with organic ingredients that activate TRP ion channels to boost neuromuscular performance, intended for endurance athletes such as runners, cyclists, and triathletes. The product is NSF Certified for Sport, non-GMO Project Verified, and USDA Certified Organic.

2FLX-787
CategoryNeuromuscular pharmaceutical candidate
Description

A clinical-stage chemical neurostimulation drug candidate that topically activates TRPV1 and TRPA1 ion channels in the mouth, throat, esophagus, and stomach to inhibit neuronal circuits and reduce alpha-motor neuron hyperexcitability. Developed for the potential treatment of muscle cramps, spasms, and spasticity associated with neurological disorders including ALS and Multiple Sclerosis.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1LMNT (Elemental Labs)
TypeEmerging player
Description

DTC electrolyte mix brand popular among endurance and strength athletes; recent entrant competing directly for HOTSHOT's premium-hydration positioning.

TypeEmerging player
Description

Performance and recovery brand combining wearable tech and topicals for athletes; adjacent competitor pursuing the same endurance-athlete recovery and cramp-adjacent categories.

TypeDirect peer
Description

Electrolyte capsule brand specifically marketed for muscle cramp prevention during endurance exercise; closest like-for-like competitor targeting the same cramp pain point.

TypeDirect peer
Description

Pioneer of the pickle juice shot for exercise-associated muscle cramps; the most direct consumer-product competitor to HOTSHOT in the cramp-prevention category among endurance athletes.

TypeDirect peer
Description

Sports nutrition brand making hydration and exercise products targeted at endurance athletes; competes with HOTSHOT for the same athlete wallet with broader product breadth.

TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company developing muscle activators for neuromuscular diseases; comparable to the FLX-787 program in mechanism rationale (targeting motor-neuron hyperexcitability and muscle function) and indication focus.

TypeBroad incumbent
Description

Neurology-focused pharma with marketed spasticity therapies (e.g., dalfampridine for MS); relevant overlap with FLX-787's spasticity in MS patient population.

TypeBroad incumbent
Description

Premium supplement/nutraceutical brand with NSF Certified for Sport products; competes with HOTSHOT among credentialed, quality-conscious endurance athletes.

TypeBroad incumbent
Description

Large-scale hydration/electrolyte brand now owned by Unilever; competes broadly in the endurance and active-lifestyle hydration category with substantially greater distribution and marketing spend.

10Nuun (Nuun & Company)
TypeDirect peer
Description

Effervescent electrolyte tablet brand owned by Nestlé Health Science; competes in hydration/cramp-prevention within the endurance and everyday-active consumer category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flex Pharma

Neuromuscular Therapeuticsflex-pharma.com

Flex Pharma was a clinical-stage biopharmaceutical company that developed chemical neurostimulation technology (TRPV1/TRPA1 ion channel activators) for muscle cramps and spasticity, commercializing the HOTSHOT consumer sports product and the FLX-787 drug candidate.

What Flex Pharma does

Flex Pharma was a clinical-stage biopharmaceutical company founded in 2014 by Nobel Laureate Rod MacKinnon, M.D. (2003 Nobel Prize in Chemistry) and Harvard neurobiology professor Bruce Bean, Ph.D., both National Academy of Science members. The company's core technology centered on chemical neurostimulation through activation of Transient Receptor Potential (TRP) ion channels — specifically TRPV1 and TRPA1 — to reduce alpha-motor neuron hyperexcitability and thereby prevent or treat muscle cramps, spasms, and spasticity. Its two product lines were HOTSHOT, a direct-to-consumer sports shot for endurance athletes that used organic, non-GMO, NSF-Certified ingredients to activate TRP channels orally; and FLX-787, a proprietary drug candidate in clinical development targeting cramps, spasms, and spasticity associated with ALS, Multiple Sclerosis, and other neurological conditions.

The company generated revenue through two distinct streams: consumer product sales of HOTSHOT via its own e-commerce storefront (a product-led, one-time-purchase model), and prospective licensing/royalty economics from future commercialization of FLX-787. GTM was hybrid — direct-to-consumer for HOTSHOT targeting endurance athletes, and clinical-development-led for FLX-787 with presentations at AAN, ASENT, ACTRIMS, SFN, ACSM, and ECTRIMS medical conferences. The company was headquartered at 800 Boylston St., 24th Floor, Boston, MA, raised $40M in a 2014 funding round from investors including Bessemer Venture Partners, Spark Capital, Longwood Fund, and Lightstone Ventures, and was associated with NASDAQ ticker FLKS. Notably, as of 2025 the flex-pharma.com domain appears to have been repurposed as a Canadian online pharmacy affiliate selling generic erectile dysfunction medications (Cialis/Viagra), suggesting the original biotech operations have ceased.

Flex Pharma firmographics

Firmographics
Name
Flex Pharma
Legal name
Flex Pharma, Inc.
Website
https://flex-pharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Flex Pharma was a clinical-stage biopharmaceutical company that developed chemical neurostimulation technology (TRPV1/TRPA1 ion channel activators) for muscle cramps and spasticity, commercializing the HOTSHOT consumer sports product and the FLX-787 drug candidate.
Ownership category
akta.pro rank

Flex Pharma industry classification

Industry
Product category
Neuromuscular Therapeutics
NAICS
Sporting and Athletic Goods Manufacturing (33992), Food (Health) Supplement Retailers (456191)
SIC
Sporting & Athletic Goods, Nec (3949), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYCRADAGAA
Sports Nutrition (Protein, Creatine, Pre-Workout/Intra-Workout)
SECONDARYHLAKALAB
Sports Medicine
SECONDARYHSADAFAD
Sports Nutrition & Performance Fueling

Keywords

  • Muscle cramp treatment
  • Neuromuscular disorder therapy
  • TRP ion channel therapeutics
  • Sports nutrition shots
  • Chemical neurostimulation

Where Flex Pharma is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Flex Pharma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. HOTSHOT Consumer Product Sales: Direct-to-consumer sales of HOTSHOT, a sports nutrition product marketed to endurance athletes for preventing and treating muscle cramps. The product is NSF Certified for Sport, non-GMO Project Verified, and USDA Certified Organic.
  2. Drug Development (FLX-787): Development of pharmaceutical products for neuromuscular disorders including FLX-787 for cramps, spasms, and spasticity associated with neurological conditions such as ALS and Multiple Sclerosis.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Flex Pharma product offering

Product offering

Core offering

Flex Pharma develops treatments for muscle cramps and spasms grounded in proprietary chemical neurostimulation technology that activates TRPV1 and TRPA1 ion channels. Its commercial offering is HOTSHOT, a consumer sports nutrition shot marketed to endurance athletes for preventing and treating muscle cramps, while its clinical-stage offering is FLX-787, a drug candidate targeting cramps, spasms, and spasticity in neurological disorders such as ALS and Multiple Sclerosis.

Product overview

Flex Pharma is a biopharmaceutical company developing treatments for neuromuscular disorders with two distinct product lines: HOTSHOT, a consumer sports nutrition product marketed to endurance athletes for preventing muscle cramps; and FLX-787, a proprietary drug candidate in clinical development targeting muscle cramps and spasticity associated with neurological conditions through a novel chemical neurostimulation mechanism.

Differentiator

Problem solved

Functional benefit

Brands

  • HOTSHOT: A proprietary sports shot with a kick, scientifically proven to prevent and treat muscle cramps. Non-GMO Project Verified, USDA Certified Organic product that is NSF Certified for Sport. Invented by Nobel Prize-winning neuroscientist Rod MacKinnon.

Products and services

  • HOTSHOT A proprietary sports shot invented by Nobel Laureate Rod MacKinnon, scientifically proven to prevent and treat muscle cramps. Formulated with organic ingredients that activate TRP ion channels to boost neuromuscular performance, intended for endurance athletes such as runners, cyclists, and triathletes. The product is NSF Certified for Sport, non-GMO Project Verified, and USDA Certified Organic.
  • FLX-787 A clinical-stage chemical neurostimulation drug candidate that topically activates TRPV1 and TRPA1 ion channels in the mouth, throat, esophagus, and stomach to inhibit neuronal circuits and reduce alpha-motor neuron hyperexcitability. Developed for the potential treatment of muscle cramps, spasms, and spasticity associated with neurological disorders including ALS and Multiple Sclerosis.

Companies that use Flex Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Flex Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Flex Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Flex Pharma competitors and assessment

Company assessment

Emerging players

  • LMNT (Elemental Labs): DTC electrolyte mix brand popular among endurance and strength athletes; recent entrant competing directly for HOTSHOT's premium-hydration positioning.
  • Hyperice: Performance and recovery brand combining wearable tech and topicals for athletes; adjacent competitor pursuing the same endurance-athlete recovery and cramp-adjacent categories.

Direct peers

  • SaltStick: Electrolyte capsule brand specifically marketed for muscle cramp prevention during endurance exercise; closest like-for-like competitor targeting the same cramp pain point.
  • Pickle Juice Company: Pioneer of the pickle juice shot for exercise-associated muscle cramps; the most direct consumer-product competitor to HOTSHOT in the cramp-prevention category among endurance athletes.
  • Skratch Labs: Sports nutrition brand making hydration and exercise products targeted at endurance athletes; competes with HOTSHOT for the same athlete wallet with broader product breadth.
  • Nuun (Nuun & Company): Effervescent electrolyte tablet brand owned by Nestlé Health Science; competes in hydration/cramp-prevention within the endurance and everyday-active consumer category.

Broad incumbents

  • Cytokinetics: Clinical-stage biopharmaceutical company developing muscle activators for neuromuscular diseases; comparable to the FLX-787 program in mechanism rationale (targeting motor-neuron hyperexcitability and muscle function) and indication focus.
  • Acorda Therapeutics: Neurology-focused pharma with marketed spasticity therapies (e.g., dalfampridine for MS); relevant overlap with FLX-787's spasticity in MS patient population.
  • Thorne (Thorne HealthTech): Premium supplement/nutraceutical brand with NSF Certified for Sport products; competes with HOTSHOT among credentialed, quality-conscious endurance athletes.
  • Liquid IV (Unilever): Large-scale hydration/electrolyte brand now owned by Unilever; competes broadly in the endurance and active-lifestyle hydration category with substantially greater distribution and marketing spend.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Flex Pharma social profiles

Digital presence

Flex Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flex Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Flex Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flex Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flex Pharma

What does Flex Pharma do?

Flex Pharma develops treatments for muscle cramps and spasms grounded in proprietary chemical neurostimulation technology that activates TRPV1 and TRPA1 ion channels. Its commercial offering is HOTSHOT, a consumer sports nutrition shot marketed to endurance athletes for preventing and treating muscle cramps, while its clinical-stage offering is FLX-787, a drug candidate targeting cramps, spasms, and spasticity in neurological disorders such as ALS and Multiple Sclerosis.

Is Flex Pharma a public or private company?

Flex Pharma is a private company. It is classified as public and is currently operating.

When was Flex Pharma founded?

Flex Pharma was founded in 2014. It employs 11 to 50 people.

Where is Flex Pharma based?

Flex Pharma is headquartered in Boston, United States, in the North America region.

How does Flex Pharma make money?

Two revenue lines are on record. HOTSHOT Consumer Product Sales are the primary driver. The others are drug Development (FLX-787).

Who are Flex Pharma's main competitors?

Emerging players on record are LMNT (Elemental Labs) and Hyperice. Direct peers are SaltStick, Pickle Juice Company, Skratch Labs and Nuun (Nuun & Company). Broad incumbents are Cytokinetics, Acorda Therapeutics, Thorne (Thorne HealthTech) and Liquid IV (Unilever).

Does Flex Pharma have an API?

No public API is recorded for Flex Pharma.

What industry is Flex Pharma in?

Flex Pharma's product category is Neuromuscular Therapeutics. Its primary akta.pro industry code is CRADAGAA, Sports Nutrition (Protein, Creatine, Pre-Workout/Intra-Workout), with a secondary code of HLAKALAB, Sports Medicine. Its NAICS code is 33992 and its SIC code is 3949.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSalarius Pharmaceuticals Reports Three and Nine Month 2019 Financial ResultsSalarius Pharmaceuticals reported Q3 2019 net loss of $2.6 million and entered a $10.9 million stock purchase agreement with Aspire Capital. The company completed its merger with Flex Pharma and listed on Nasdaq, with $4.0 million in cash and $9.1 million remaining from a CPRIT grant.PR NewswireSalarius Pharmaceuticals to Present at the 2019 World Orphan Drug CongressSalarius Pharmaceuticals announced that its Business Development Manager will present at the World Orphan Drug Congress USA 2019 on April 12, 2019, in Oxon Hill, Maryland, focusing on Seclidemstat, its investigational LSD1 inhibitor for Ewing's sarcoma currently in Phase 1 trials. The company has received Orphan Drug designation and Rare Pediatric Disease designation from the FDA for Seclidemstat and is also developing it for other cancers including prostate, breast, and ovarian. The announcement also noted Salarius's proposed merger with publicly traded Flex Pharma, Inc., expected to close in the first half of 2019.PR NewswireLifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., TLifshitz & Miller LLP announced investigations into potential breaches of fiduciary duties regarding the sales or corporate actions involving AmpliPhi Biosciences, Churchill Capital, Flex Pharma, MYnd Analytics, SunCoke Energy Partners, Top Image Systems, and Uniti Financial. Additionally, the firm reported that a US District Court denied DaVita Inc.'s motion to dismiss a pending securities class action.PR NewswireSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flex Pharma, Inc. - FLKSMonteverde & Associates PC announced an investigation into the Board of Directors of Flex Pharma, Inc. regarding the proposed sale of the company to Salarius Pharmaceuticals, LLC. The investigation concerns whether the board violated securities laws and breached fiduciary duties by failing to properly value the transaction and disclose all material financial information ahead of a shareholder vote. Under the proposed terms, Flex Pharma stockholders would retain a 19.9% stake in the combined company upon completion.PR NewswireThinking about buying stock in Advanced Micro Devices, Canopy Growth Corp, Facebook, Flex Pharma or Snap Inc.?InvestorsObserver issued PriceWatch Alerts for stocks including Advanced Micro Devices, Canopy Growth Corp, Facebook, Flex Pharma, and Snap Inc. on January 7, 2019. The alerts utilize a proprietary scoring methodology that combines short-term technical, long-term technical, and fundamental factors to evaluate investment suitability.Houston ChronicleHouston-based Salarius to merge with Flex PharmaSalarius Pharmaceuticals will merge with Flex Pharma to boost development of rare cancer treatments. The combined company will carry the Salarius name and be led by Salarius' management, with the merger expected in the first half of this year. Salarius' lead compound Seclidemstat targets Ewing sarcoma, with trials for other cancers planned later this year.PR NewswireRosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Flex Pharma, Inc.; Important Aug. 20 Deadline - FLKSRosen Law Firm announced the filing of a securities class action lawsuit against Flex Pharma, Inc. on behalf of investors who purchased company securities between November 6, 2017 and June 12, 2018. The lawsuit alleges that Flex Pharma made false and misleading statements regarding the viability and approval prospects of its product candidate FLX-787 for treating ALS and CMT. Investors who wish to serve as lead plaintiff must move the Court by August 20, 2018.PR NewswireLifshitz & Miller LLP Announces Investigation of Education Realty Trust, Inc., Flex Pharma, Inc. (FLKS), Netshoes (Cayman) Limited, Northwest Bancorporation, Inc., Pinnacle Foods, Inc., Restoration RoLifshitz & Miller LLP announced investigations into potential securities violations or fiduciary duty breaches for nine publicly traded companies, including Education Realty Trust, Flex Pharma, and Netshoes. The firm is soliciting investors from these entities to complete information requests regarding the specific allegations against each company.PR NewswireEQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Flex Pharma, Inc. - FLKSThe Rosen Law Firm filed a securities class action lawsuit against Flex Pharma, Inc. on July 19, 2018, alleging the company made false and/or misleading statements regarding the viability and approval prospects of its product candidate FLX-787 for treating ALS and CMT during the class period of November 6, 2017 to June 12, 2018. The lawsuit, filed on behalf of securities purchasers, seeks damages under federal securities laws and claims investors suffered losses when the true details entered the market. A lead plaintiff motion deadline of August 20, 2018 has been set.